Next Antidepressant Choice After Failed Sertraline and Escitalopram
Based on the pharmacogenomic testing results, select an antidepressant that is NOT primarily metabolized by CYP2C19 or CYP2D6, such as bupropion, mirtazapine, or venlafaxine, depending on the specific genetic variants identified.
Understanding the Pharmacogenomic Context
Your patient has now failed two SSRIs (sertraline and escitalopram), both of which are primarily metabolized by CYP2C19 1. The pharmacogenomic testing you ordered likely revealed variants in CYP2C19 and/or CYP2D6 that explain these failures. Here's how to interpret and act on those results:
If CYP2C19 Increased Metabolizer (Ultrarapid or Rapid):
- Problem: The patient metabolizes SSRIs too quickly, leading to subtherapeutic drug levels and poor response
- Sertraline and escitalopram are both heavily dependent on CYP2C19 for metabolism 1
- Recent data shows CYP2C19 increased metabolizers have significantly higher discontinuation rates for escitalopram (HR=1.27) and sertraline (HR=1.15) 2
- Avoid: Other CYP2C19-dependent drugs (citalopram, escitalopram, sertraline)
If CYP2D6 Poor or Intermediate Metabolizer:
- Problem: The patient metabolizes certain antidepressants too slowly, leading to excessive drug levels and adverse effects (potentially explaining the "major breakdown" on Lexapro)
- Avoid: Paroxetine, venlafaxine (though venlafaxine may still be considered with dose adjustment), and vortioxetine 1
Recommended Next Steps
First-Line Recommendation: Bupropion
- Not metabolized by CYP2C19 or CYP2D6 as primary pathway
- Different mechanism of action (norepinephrine-dopamine reuptake inhibitor vs. SSRI)
- Proven cost-effective after SSRI failure 3
- Starting dose: 150 mg daily, can increase to 300 mg after one week
- Advantages: Lower sexual dysfunction risk, may help with fatigue/energy
- Cautions: Avoid if seizure history, eating disorders, or high anxiety
Alternative Option: Mirtazapine
- Minimal CYP450 involvement in metabolism
- Different mechanism (alpha-2 antagonist, increases norepinephrine and serotonin)
- Starting dose: 15 mg at bedtime
- Advantages: Helps with sleep and appetite, rapid onset (1-2 weeks)
- Cautions: Sedation and weight gain are common
Consider if Specific Genotype Allows: Venlafaxine
- Only if NOT a CYP2D6 poor metabolizer (increased discontinuation risk in decreased metabolizers, HR=1.23) 2
- Dual mechanism (SNRI) may be beneficial after SSRI failure
- Starting dose: 37.5-75 mg daily
- Cautions: Monitor blood pressure, taper carefully when discontinuing
Critical Caveat About Pharmacogenomic Testing
The evidence for using CYP450 testing to guide SSRI selection remains limited 4. The 2007 EGAPP guidelines found insufficient evidence that CYP450 testing improves clinical outcomes, noting that "CYP450 genotypes are not consistently associated with clinical response to SSRI treatment or adverse events" 4. However, the 2016 Mayo Clinic guidelines support using pharmacogenomic data when available to guide prescribing 1.
The practical approach: Since you already have the testing results, use them to avoid medications that are poor matches for the patient's metabolizer status, but don't expect the testing alone to guarantee success.
What NOT to Do
- Don't simply increase the dose of sertraline or switch to another SSRI metabolized by CYP2C19 (citalopram) if the patient is an increased metabolizer
- Don't ignore the "major breakdown" on escitalopram—this suggests either excessive drug levels (if poor metabolizer) or inadequate response with emerging adverse effects
- Don't rely solely on pharmacogenomic testing—consider other factors like comorbid anxiety, bipolar spectrum features (which would require mood stabilizer first) 5, and patient preference
Monitoring the New Medication
- PHQ-9 score of 9 indicates mild depression—reassess at 2-4 weeks
- Target: PHQ-9 reduction of ≥50% or score <5 for remission
- If no response by 6-8 weeks at therapeutic dose, consider augmentation (lithium, lamotrigine, or atypical antipsychotic) rather than another switch 5, 6
- Screen for bipolar features before each medication trial—unrecognized bipolarity is a leading cause of "treatment resistance" 5